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Abstract 
Erythropoietin (EPO) is the main erythropoiesis hormone, activates the 
progenitor red blood cells through proliferation, differentiation, and maturation 
of red blood cells. However, it's another receptor in other tissues, including 
heart and endothelium, confirm its pluripotent activities. Numerous preclinical 
studies have shown EPO would be cardioprotective against ischemic events, 
reperfusion injury and apoptosis. The results of EPO in clinical studies were 
inconclusive with even associated increased risk of adverse outcomes. In this 
article, a comprehensive review of the EPO effects is evaluated in coronary 
artery disease, cardiac surgery, heart failure, and its safety through the results 
of the most recent clinical trials related to EPO in cardiovascular disease. The 
analysis of the available clinical trials demonstrates the most determining 
factors; EPO dose and administration time related to myocardial ischemia 
onset. It seems the low dose EPO treatment has a tissue-protective effect 
through its receptors, while the higher doses of EPO stimulate the other EPO 
receptors responsible for erythropoiesis. The safety of high dose EPO therapy 
to increase the risk of thrombotic complications has been controversial. The 
erythropoiesis-stimulating agents have been proven to successfully correct 
hemoglobin levels, reduce the need for blood products after surgery and can 
improve the clinical outcomes, without increased thromboembolic risk. 
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Introduction 
Erythropoietin (EPO) has been known as an 
essential part of erythropoiesis. With the detection of 
EPO receptors in non-hematopoietic tissue, its 
immunomodulatory properties and cardioprotective 
functions have been identified (1, 2). Numerous 
experimental data support the pleiotropic properties of 
EPO to inhibit apoptosis in the ischemic myocardium, 
stimulation of endothelial progenitor cell (EPCs), less 
migration of inflammatory cells and have effective 
pro-angiogenic properties. In animal models of 
myocardial ischemic injury, EPO administration has 
been shown to reduce infarct size with secured 
ventricular function dramatically (3-5). 
These findings have attracted growing interest 
in the use of EPO in ischemic heart disease, 
particularly in the treatment of myocardial infarction 
(MI) as the cardioprotective role for EPO found in 
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experimental models (1, 3). In recent years, several 
trials examined the effects of EPO treatment in patients 
with MI and heart failure (HF) that have been 
associated with inconclusive results. This article 
provides a comprehensive review of the 
cardioprotective effects of erythropoiesis-stimulating 
agents, including recombinant human EPO and its 
analog darbepoetin through the results of the most 
recent clinical trials. 
 
EPO definition 
EPO was recognized to play a major role in the 
regulation of erythropoiesis in 1977. EPO is a 
glycoprotein hormone-containing 165 amino acids 
with a molecular weight of 30.4 kDa. It is 
predominantly produced by peritubular interstitial 
fibroblasts of the cortex and outer medulla in the 
kidney. Its synthesis is stimulated by tissue hypoxia 
when renal function is intact. It induces erythropoiesis 
and regulates peripheral oxygenation (4-7). Due to the 
limited life span of red blood cells, EPO stimulates the 
production of more than 200 billion red blood cells 
every day to compensate it (2, 8). Serum EPO 
concentration is a range of 10- 25 units/l (1). There is 
a time interval (several hours) between an injury and 
EPO gene expression (5). Both local hypoxia (renal 
hypoperfusion) and general hypoxia (anemia, HF, 
pulmonary diseases) trigger increased EPO production 
(9). Malnutrition and inflammatory state (through pro-
inflammatory cytokines) lead to erythropoietin 
resistance (7). Now it is known as a marker of hypoxia 
and inflammation (9). With the introduction of 
recombinant human erythropoietin since 1989, it has 
been approved for the treatment of anemia associated 
with chronic renal failure and malignancy to improve 
quality of life, and prior to major surgeries to reduce 
postoperative blood transfusion requirements (3). 
There is a 2 to 3 days interval between exogenous EPO 
administration and an increase in reticulocyte count, so 
it is recommended to be given days before the 
scheduled intervention (10, 11). 
EPO receptors are expressed in different tissues 
such as the kidney, central nervous system, endothelial 
cells and cardiac tissue (4, 12-14). Following binding 
of EPO to its receptor, activates multiple signaling 
pathways in different cell types, results in its action. 
This suggests the cytoprotective effects of the 
paracrine EPO axis (1, 3, 12). EPO can bind to the 
cardiomyocyte surface receptors and effectively inhibit 
the apoptosis of cardiomyocytes through a series of 
reactive pathways, which is beneficial to their survival. 
At the same time, it can also mobilize EPCs to promote 
angiogenesis, endothelial repair and myocardial 
regeneration in the damaged myocardium. In addition, 
intracellular calcium ions increase with myocardial 
reperfusion, EPO creates a balance in intracellular 
calcium ions and pH (15). 
Erythropoietin-stimulating agents are 
biologically active drugs used to trigger erythropoiesis 
with greater metabolic potency and longer half-life (8, 
16-18). They are commonly used in patients with 
advanced stages of chronic kidney disease and include 
epoetin α, epoetin-beta, darbepoetin α, and continuous 
EPO receptor activator (16). Overall, these agents 
should be avoided in patients with mild or moderate 
anemia as they do not generally improve outcomes but 
may increase the risk of venous thromboembolic 
events (16). 
 
Endogenous EPO level, good or bad? 
Impairment of EPO production is the main 
cause of anemia in HF patients with renal disease. 
However, the endogenous EPO level may be high in 
HF patients with anemia due to bone marrow resistance 
to EPO. Resistance to EPO has been associated in an 
inflammatory state which is often present in these 
patients (9). It seems the high endogenous EPO level is 
associated with increased risk of adverse outcomes in 
HF patients (both chronic HF and acute 
decompensated HF) (9, 19, 20). In addition, the EPO 
level has prognostic significance to predict the risk of 
future adverse events in HF patients (20). The high 
EPO level could exist before the development of 
clinical signs and symptoms of HF (9). Higher levels 
of endogenous EPO are associated with incident HF in 
the community-living older adults (19). 
Except for HF, the association between EPO 
levels with other cardiovascular events was not found. 
There is a strong association between the endogenous 
EPO level and some indicators of metabolic syndrome 
like waist circumference, blood sugar level, and 
hypertension. This confirms that EPO acts as an index 
of hypoxia and inflammation and disease severity (9). 
The hypoxia-inducible factor 1𝛼 (HIF-1α) is 
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defined to determine the EPO expression. A high level 
of HIF-1𝛼 has been associated with ischemic 
preconditioning and cardioprotective effect. In other 
words, short episodes of myocardial ischemia up-
regulate HIF-1𝛼 and increase the endogenous EPO 
level, which may protect the heart against a subsequent 
acute MI (9). 
Remote ischemic preconditioning is a well-
known protective and endogenous defense mechanism 
in which brief episodes of non-lethal ischemia with 
subsequent reperfusion, limit the myocardial infarct 
size (21). An observation showed the transient limb 
ischemia of the upper arm in human reduces renal 
blood flow and increase serum EPO level (21). Its 
potential cardioprotective impact has not been assessed 
in humans yet (21). But the serum EPO level is found 
to be higher in MI patients (from admission to 7 days), 
independent of the hemoglobin (Hb) level (22). In 
patients with coronary artery disease, the increased 
serum EPO level has been associated with an increased 
number and activity of circulating EPCs, stem cells and 
progenitor cells in bone marrow (23). The high 
endogenous EPO level may be associated with smaller 
infarct size in primary percutaneous coronary 
intervention (PCI) patients (23). Serum EPO level is a 
useful biomarker for the development of coronary 
collateral in patients with chronic total coronary 
occlusion. In another observational study in patients 
with chronic total occlusion, the serum EPO level was 
significantly higher in patients with better coronary 
collateral vessel grades (24). 
The endogenous EPO level is associated with 
the changes of electrocardiogram scatter plot in 
patients with coronary artery disease and autonomic 
nerve function injury. Both the endogenous EPO level 
and length of scatter plot have a similar diagnostic 
value on predicting of autonomic nerve function injury 
(25). 
Conflict results: One study showed coronary 
collateral development is related to anemia and not the 
serum EPO level (26). In patients with acute coronary 
syndrome, the serum level of EPO may be an important 
biomarker of the development of kidney injury and in-
hospital mortality (27). A cross-sectional study showed 
the EPO levels in the coronary artery disease group 
were significantly higher than the control group. There 
was a statistical association between endogenous EPO 
level and increases in red cell distribution width 
(RDW) in coronary patients. It seems both increased 
EPO and RDW might be risk factors for the 
development of coronary artery disease (28). 
 
EPO treatment and coronary artery disease 
The endogenous EPO increases red blood cell 
production at low oxygen state to increase oxygen 
delivery in response to ischemic stress (8). The strong 
cardioprotective effect of EPO administration was 
proven in numerous experimental models through 
inhibiting apoptosis, reducing migration of 
inflammatory cells, promoting angiogenesis, 
mobilizing EPCs, and thereby protect cardiac repair 
after MI (2, 3, 27, 29). Further studies have shown EPO 
treatment may have no similar and promising effects in 
different species. Several randomized controlled trials 
were designed to find the efficacy of EPO treatment for 
acute myocardial support in MI patients, with the 
difference in dosing, interval time to reperfusion, 
delivery route, and administration times. However 
clinical studies did not show consistent and convincing 
benefit in terms of an improvement in ejection fraction 
(EF) and reduction in infarct size (11, 12, 17, 19, 29). 
In 2015, a meta-analysis and the systematic 
review showed short-term administration of EPO in MI 
patients undergoing PCI does not result in significant 
improvement in echocardiographic findings including 
EF and volumes of the left ventricle during cardiac 
cycles, reduction of infarct size and all-cause mortality. 
The incidence of new MI, stent thrombosis and major 
adverse cardiac events in the EPO group have not 
statistically difference compared to the control group 
(11). Recently, a randomized -controlled multicenter 
study (including 25 hospitals) in Japan tried to 
determine the efficacy and safety of low-dose EPO 
(6000 vs.12000 IU vs. placebo, within 6 h of successful 
PCI in MI patients). There was no difference in EF 
improvement and adverse events at 6 months among 
the three groups (30). In another study, 5- year follow 
up data of MI patients (who received EPO treatment 
during PCI) showed that epoetin beta does not improve 
clinical outcomes (31). In ICEBERG trial in 2019, 
intracoronary darbepoetin-α administration before 
balloon inflation in MI patients did not reduce infarct 
size (17). 
The therapeutic window for EPO treatment 
Erythropoietin in the clinical trials of the cardiac disease, what is and what is not                      Majidi Tehrani and Foroughi  
Vol 4, No 4, Fall 2019 
139 
during MI is very narrow and was possibly neglected 
in negative clinical trials (32). It seems the optimal 
time for EPO the administration should be just prior to 
PCI and preceding ischemic-reperfusion injury (1, 11, 
15, 17, 31, 32). 
This variation about the role of EPO exists in 
endothelial cells, too. Darbepoetin has been shown 
atheroprotective, and in patients with coronary artery 
disease improves endothelial function and increases 
circulating EPC number (33). In another clinical study, 
darbepoetin administration prior to ischemic-
reperfusion injury enhanced endothelial function (34). 
On the other hand, in hemodialysis patients, high dose 
EPO treatment might reduce the numbers of CD34 + 
cells, accelerate atherosclerosis and increased 
cardiovascular-related mortality (35). The CD34 + 
cells are peripheral blood mononuclear cell 
populations, lead to endothelial regeneration (35). 
Hemodialysis patients have chronic inflammation and 
endothelial dysfunction. 
In another study the selected inflammatory 
biomarkers related to cardiovascular risk (IL-1β, TNF-
RI, TNF-RII, sFas, sFasL, MMP-9, TIMP-1, and TGF-
β1), endothelial dysfunction markers (sE-selectin, 
sICAM-1, and sVCAM-1), and volume-related marker 
(NT-pro BNP) measured and found significantly 
increased in patients with chronic kidney dysfunction 
compared to controls. EPO treatment in these patients 
showed anti-inflammatory action, less endothelial 
dysfunction with an improvement of left ventricular 
function (36). Cardiorenal syndrome patients showed 
reduced CD34 and EPC levels compared to controls, 
neither short nor long-term EPO therapy show a 
significant influence on reduced EPC levels (36). 
The administration of EPO before PCI in MI 
patients showed the protective role in vascular 
endothelial cell function and improvement of the 
body's neuroendocrine hormone levels. These 
endothelial cell markers were measured before and 
after intervention: type I collagen carboxy-terminal 
peptide as a newly myocardial maker related to the 
degree of plaque instability, homocysteine as the 
independent risk factors of occurrence of coronary 
disease, endothelin-1 induce vasospasm and von 
Willebrand factor which promotes the massive 
production of platelets and forms microthrombus. The 
measurement of all endothelial cell markers were 
lower levels in the EPO group. The levels of 
neuroendocrine hormones (cortisol, adrenocortical 
hormone, norepinephrine and angiotensin II) were 
lower in EPO group, indicating that EPO treatment 
with PCI can inhibit the activation of the 
neuroendocrine system (15). 
Even in the cardiac arrest setting, EPO has been 
suggested to be added in the therapeutic strategy, due 
to its anti-apoptotic, anti-inflammatory, antioxidative, 
and its angiogenic properties (37). 
In addition to primary PCI and standard 
antiplatelet therapy in MI patients, high dose 
administration of EPO reduces the incidence of 
arrhythmias. It may prevent the release of free radicals 
from neutrophils or behave as a free radical scavenger 
(38). 
There have been numerous clinical trials with no 
clear evidence of EPO efficacy. Two types of EPO 
receptors were detected. The erythropoietic effect of 
EPO is mediated by the classical EPO receptor in high 
dose EPO treatment, while the tissue-protective effect 
of EPO may be mediated by the up-regulation of beta 
common receptors after tissue injury only in low dose 
EPO treatment (13, 14, 39). 
 
EPO treatment in heart failure patients 
EPO in addition to the hematopoietic effect 
attenuates ventricular remodeling (by stimulating new 
vessel formation) and improve cardiac function in 
experimental models of HF (1, 3, 9, 20, 29). 
Both anemia and iron deficiency are common 
comorbidities in HF patients and associated with the 
increased morbidity and mortality (6, 7, 40). The high 
prevalence of anemia in HF patients could be attributed 
to the inflammatory state, renin-angiotensin system 
activation, deficiency or resistance to endogenous 
EPO, hemodilution and reduced iron absorption (9, 40-
42). Less response to EPO may be the reflection of 
chronic inflammatory status seen in HF patients (19, 
43). Medication such as β-blockers and inhibitors of 
the renin-angiotensin the system has been associated 
with a reduced effect of EPO (43). Increased 
proinflammatory cytokines associated with the chronic 
state in HF patients are inversely related to Hb level 
(40). With renal hypoperfusion in HF patients, EPO 
level increased in proportion to HF grade, but it is not 
comparable to the degree of Hb (40). It seems anemia 
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would be a marker of disease severity (not a 
therapeutic target), as treatment is not associated 
necessarily with clinical improvement (40). It was 
shown the inverse association between severe anemia 
and the left ventricular mass, the EF and the renal 
function (44, 45). It seems to be an independent marker 
of HF severity and not an indicator of poor outcomes. 
On the other hand, there is a reverse association 
between EF and Hb (40). The increase in Hb leads to 
an increase in blood volume and viscosity, 
hypertension, and increased risk of stroke due to an 
increase in systemic vascular resistance, raise the left 
ventricular afterload and lead to reduced EF (19, 40). 
In another study, about half of the HF patients 
with anemia had normal to high levels of EPO in blood 
samples which could indicate the low response of the 
bone marrow (42, 46). It was shown the association of 
increased circulating EPO level with higher functional 
class, the level of BNP and increased risk of recurrent 
HF hospitalization and mortality (19). The well-
functioning community-living older persons with 
elevated levels of serum EPO are at increased risk of 
incident HF. This association is independent of the 
cardiovascular risk factors, inflammatory markers, 
kidney function and anemia status (19). 
These confirm the importance of the EPO level 
in all patients with HF before and after treatment with 
the aim of anemia correction. The measurement of 
EPO in both chronic and acute decompensated HF 
patients could be used as a surrogate marker and 
indicator of adverse outcomes, independent of Hb level 
(1, 6, 9, 20). Treatment with ACE inhibitors in HF 
patients has been associated with a reduction in serum 
EPO levels in addition to clinical and hemodynamic 
improvements (1). 
In small uncontrolled or randomized placebo-
controlled studies, EPO treatment have improved HF 
symptoms and functional capacity but its effect on 
reduction in all-cause mortality has been borderline 
with no significant adverse effect (7, 40). But in the 
large pivotal RED-HF trial (Darbepoetin alfa treatment 
for systolic HF patients with anemia), including 2278 
patients, despite Hb improvement, darbepoetin failed 
to improve outcomes (death from any cause or 
hospitalization for worsening HF) over placebo, while 
increased the risk of thromboembolic events (7, 40, 
42). Therefore, in patients with HF and anemia, 
darbepoetin is not recommended to be used (class III) 
(47). A post hoc analysis of the RED-HF trial showed 
one-quarter of HF patients with anemia, had a poor 
response to darbepoetin alfa treatment after 4 weeks. 
This poor hematopoietic response was associated with 
the worse outcomes independent of other prognostic 
factors. Despite the use of higher doses of EPO in these 
patients, they did not have an increased rate of 
thromboembolic events. It was suggested that in 
patients without an initial increase in Hb level, EPO 
treatment should be stopped (46). 
Administration of EPO to anemic HF patients 
(both systolic and diastolic HF) corrected anemia but 
neither result in significant improvement in cardiac 
structure and function nor improved clinical outcomes. 
It seems that Hb would be a surrogate marker of poor 
prognosis rather than a therapeutic option (42, 44). 
There is no recommendation to correct mild to 
moderate anemia by EPO, although correctable causes 
should be treated (40). 
The risk and benefit of EPO treatment should be 
balanced in HF patients with chronic kidney disease, 
as it may increase the risk of cardiovascular events and 
mortality (48). 
However, using erythropoiesis-stimulating 
agents in patients with anemia and HF is now only 
recommended in chronic kidney disease patients (7, 
19, 40, 42, 46). Overall, these agents should be avoided 
in mild or moderate anemia as they do not generally, 
improve outcomes, but may increase the risk of venous 
thromboembolic events (16, 42). 
 
EPO in cardiac surgery 
a) Acceleration of hematopoiesis 
There are mixed results in clinical trials of EPO 
in cardiovascular surgery field with more attention to 
stimulate red blood cell production and its potential 
role as a blood conservation strategy. The significant 
part of blood products is used by cardiac surgery 
patients due to the high proportion of anemia in 
patients undergoing cardiac surgery and the induced 
coagulopathy by cardiopulmonary bypass machine. A 
numerous study has shown the association between 
blood transfusion and increased adverse effects post-
cardiac surgery (10, 49, 50). A recently published 
research demonstrated single-dose subcutaneous 
erythropoietin alpha (40000 IU) with the 
Erythropoietin in the clinical trials of the cardiac disease, what is and what is not                      Majidi Tehrani and Foroughi  
Vol 4, No 4, Fall 2019 
141 
administration of intravenous iron, vitamin B12, and 
oral folic acid in anemic (or isolated iron deficiency) 
patients on the day before surgery significantly 
reduced the need for blood transfusion post-cardiac 
surgery (10). Although an increase in reticulocyte 
count after EPO treatment may be observed with 3 
days delay (10, 43). In anemic patients with severe 
aortic stenosis who referred for trans-aortic valve 
replacement, EPO (darbepoetin alfa 0.75 µg/kg) + 
200mg iron sucrose at days 10 and 1 before the 
operation failed to decrease the need for blood 
transfusion (43). Administration of intravenous 
recombinant EPO (500IU/kg weekly for 5 weeks, the 
last dose 48 hour before valve replacement) plus iron 
in anemic patients improved postoperative outcomes 
and reduced need for blood transfusions (51). The 
similar study in anemic patients undergoing valve 
surgery showed a single intravenous administration of 
EPO (500IU/kg) and an iron supplement 1 day before 
surgery reduced the perioperative blood transfusion 
significantly (52). A single high dose (80000 IU) of 
recombinant EPO administered 2 days before cardiac 
surgery in anemic patients (Hb<13 g/dL), is effective 
in reducing the blood transfusion requirement without 
adverse events increases (53). 
The recently systematic review and meta-
analysis confirm preoperative EPO administration 
significantly reduces the need to blood transfusion 
(54). 
b) Renoprotective 
Cardiac surgery-associated acute kidney injury 
(CSA-AKI) is a well-known complication with a 
significant adverse effect on early and late outcomes 
(12, 19, 55). EPO with anti-inflammatory, anti-
apoptosis and anti-oxidative properties have been 
renoprotective in experimental models (2, 5). There are 
controversial results about the efficacy of EPO for 
renal protection in cardiac surgery (36, 55). 
To assess the renoprotective effect of EPO, two 
different doses of EPO (Epoetin 20000 and 40000IU) 
compared. It was given 1-4 hours after cardiac surgery 
and arrival to the ICU. The kidney biomarkers (urinary 
NGAL concentration, serum cystatin C level) and the 
systemic inflammatory response (serum IL6 and IL8) 
had no significant differences between the groups (56). 
In another clinical trial in patients with complex 
valvular operation who were potentially high the risk 
for CSA-AKI, administration of 300IU/kg EPO 
intravenously after anesthesia induction was not 
renoprotective by serial measurement of serum 
creatinine, NGAL and cystatin C. It had no beneficial 
influence on levels of IL6 and myeloperoxidase as an 
assessment of inflammatory status (57). In elective 
coronary bypass patients,  preoperative administration 
of EPO (200 IU/kg 3 days before the operation and 100 
IU/kg following induction of anesthesia) decreased the 
incidence of CSA-AKI (58). 
The various interconnections of different factors 
lead to CSA-AKI. Although EPO has a protective role 
against ischemia, it is ineffective against inflammation 
and drug-induced renal injury (55, 57). Thus, the use 
of a single preventive strategy may not be enough to 
inhibit the numerous pathways that lead to renal injury. 
A meta-analysis of RCTs in 2014 showed the 
reduced incidence of CSA-AKI was seen in patients 
who did not have a high risk of developing CSA-AKI 
(55). Attenuation of ischemic-reperfusion injury and 
augmentation the level of erythrocyte anti-oxidative 
enzymes would be the possible mechanisms (55). 
The systematic review and meta-analysis of 
RCTs about the renoprotective role of EPO in cardiac 
surgery patients in 2016 suggest the importance of two 
variables: timing of EPO administration and stratifying 
by patients' risks. Both EPO treatments before 
anesthesia induction and EPO use in low-risk patients 
were correlated with a decrease in kidney injury post 
cardiac surgery (12). 
EPO maybe considered as preconditioning 
agent. EPO was inefficient in preventing CSA-AKI 
when administrated shortly after cardiac surgery. EPO 
treatment after CSA-AKI establishing could not able to 
end and reverse the beginning process of kidney injury. 
c) Neuroprotective 
EPO as tissue protective cytokine has shown 
direct neurobiological activity. It could be used 
clinically as neuroprotective in cardiac surgery. In a 
clinical study, 3 intravenous 24000 IU of recombinant 
EPO reduced the brain lesions detectable by MRI and 
biomarkers of neurologic injury (59). 
 
EPO safety 
There is a fragile balance between the desirable 
and undesirable effects of EPO. The investigation 
about the effect of preoperative EPO therapy on 
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platelets and hemostasis in cardiac surgery patients 
showed that preoperative EPO therapy is not 
associated with an increased thromboembolic risk (10). 
Moreover, the intracoronary administration of 
darbepoetin did not increase thrombotic complications 
in patients with MI (17). 
Nonspecific symptoms have been reported in 
chronic EPO treatment (60). The safety of high dose 
EPO therapy to increase the risk of cardiovascular 
events has been controversial (3, 7, 17, 20, 39, 42, 48, 
57, 61). The concerns about its pro-thrombotic and 
platelet-activating effects exist and there is no 
permission to use EPO treatment in the setting of 
cardiovascular disease in some countries (eg, the UK) 
(10). It has been claimed that increased Hb level may 
contribute to increased viscosity, elevated blood 
pressure and vascular thrombosis. EPO structure is 
similar to thrombopoietin, high dose EPO increases 
platelet production and adhesiveness reactivity, 
increase levels of the hemostatic factors von Wille 
brand factor and plasminogen activator inhibitor-1, so 
create a thrombogenic milieu and increased risk of 
thrombotic cardiovascular events (3, 9, 30, 48). EPO is 
known to increase vasomotor tone through the 
synthesis of endothelin and expression of Angiotensin 
II receptors in vascular endothelial cells and raises 
calcium concentrations in vascular smooth muscle 
cells (3). This is a true concern for cancer patients. EPO 
treatment may promote tumor growth, increase 
thrombotic events and mortality due to the 
hypercoagulable states (55). In the setting of 
uncontrolled hypertension, the use of EPO is 
contraindicated because both acute and long-term 
administration of EPO can exacerbate it (60). 
Use of EPO in patients with left ventricular 
assist device in order to decrease blood transfusions 
and allosensitization is concerning, as it increases 
thrombotic events and these devices are sensitive to 
pump thrombosis (62). 
The last systematic review and meta-analysis 
confirm that preoperative EPO treatment to decrease 
blood products requirement, do not increase the risk of 
thromboembolic complications (54). It should be 
emphasized that these adverse effects essentially 
happen in long-term high dose EPO treatment, while 
short-term use of EPO appears to be safe, even in 
critically ill patients. 
Conclusion 
EPO has pleiotropic cellular effects and can 
decrease inflammation, oxidative stress, apoptosis and 
stimulate angiogenesis. EPO would be used as a useful 
biomarker in the clinical management of 
cardiovascular diseases. The higher doses of EPO 
should be used cautiously with consideration of 
adverse effects such as thrombosis and hypertension. 
Erythropoiesis-stimulating agents have been proven to 
successfully correct Hb level, reduce the need to blood 
products after surgery and improvement in clinical 
outcome, without increased thromboembolic risk. 
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